We thank Tomao et al^[@b1]^ for their comments on our recent report on patient-reported outcomes (PROs) in the Suppression of Ovarian Function Suppression Trial (SOFT).^[@b2]^ When SOFT was designed more than a decade ago to investigate the role of ovarian function suppression (OFS) and the role of exemestane in premenopausal women with endocrine-responsive early breast cancer either after completion of (neo)adjuvant chemotherapy or after surgery alone,^[@b3]^ quality of life (QoL) was integrated to assess the patients' perspective. Our results provide complementary information to the adverse event reporting in SOFT^[@b2]^ and add novel information to existing evidence on the effect of OFS on PROs and QoL. In the Zoladex in Premenopausal Patients^[@b4],[@b5]^ trial, chemotherapy was given concurrently with adjuvant endocrine therapy, and the observation period was restricted to the first 2 years of treatment. Eastern Cooperative Oncology Group E-3193^[@b6]^ and SOFT are the only two randomized phase III trials presenting long-term PROs in this setting. Our article complements the findings of E-3193, but with major differences. The SOFT population is international, and the sample size is larger, with 1,722 patients available for the primary QoL analysis. The E-3193 trial presented data from a summary score of patient-reported symptoms. We found that OFS added to tamoxifen results in variable magnitudes of treatment differences for individual symptoms. The E-3193 trial only included patients without chemotherapy, whereas SOFT enrolled two distinct cohorts of patients: those with and those without prior chemotherapy. The prior chemotherapy cohort had higher-risk disease than the E-3193 trial population, which is the current target population for OFS. Cognitive function was assessed as part of a substudy.^[@b7]^ The gold standard of cognitive assessment, a comprehensive neuropsychological testing,^[@b8]^ was not feasible in the entire study population, with more than 500 centers and many different languages.

Tomao et al^[@b1]^ suggest that we did not present several clinically relevant data. With regard to treatment, in the cohort of patients with prior chemotherapy, the majority received either anthracycline-based (38%), or anthracycline plus taxane--based (53%) chemotherapy. The impact of these two different types of chemotherapy on patients' symptom experience is relevant primarily in the short term. The number of patients who were treated with human epidermal growth factor receptor 2--directed therapy (ie, trastuzumab, 8% overall) were reported in Table A1 (Data Supplement) of Ribi et al.^[@b2]^ This low percentage would not have changed our results in a meaningful way. Oral endocrine therapy before randomization was allowed while premenopausal status was established or re-established. Details on duration were included in our report (Table 1).^[@b2]^ In the overall population, three patients received an aromatase inhibitor before randomization.^[@b3]^ The number of patients with irregular menstruation or persistent amenorrhea at baseline (ie, after chemotherapy or previous endocrine therapy) were reported in Table A1 in the data supplement.^[@b2]^ We controlled for menstruation status in the mixed-effect models. During the 5 years of assigned endocrine treatment, it was not possible to accurately determine menopausal status, as we did not routinely measure hormone levels during treatment and amenorrhea during tamoxifen is not an accurate determinant of menopause.

A further criticism relates to the inclusion of patients who both did and did not receive chemotherapy before enrollment. The authors are correct that patients in the chemotherapy cohort had higher-risk disease characteristics and were younger (Table 1 in our report and Table A1 in the Data Supplement).^[@b2]^ However, the occurrence of symptoms (eg, vasomotor, gynecologic, and sexual symptoms) was not lower in this cohort. On the contrary, patients with prior chemotherapy reported worse baseline scores for these symptoms compared with the no-chemotherapy cohort, possibly caused by chemotherapy and by the receipt of tamoxifen before enrollment in half of these patients. Thus, changes over time in these symptoms were smaller (ie, less worsening) in the chemotherapy compared with the no-chemotherapy cohort, leading to the interpretation that chemotherapy did not exacerbate adverse effects. Presenting our results not only for the overall population but also separately for the two chemotherapy cohorts in our report (Appendix Figs A2A and A2B)^[@b2]^ is a strength of our study.

The efficacy results from SOFT,^[@b3]^ in conjunction with those from the SOFT plus TEXT combined analysis,^[@b9]^ are practice changing.^[@b10]^ PROs comparing exemestane versus tamoxifen in patients who received OFS were published earlier this year.^[@b11]^ The PROs of the comparison of tamoxifen plus OFS versus tamoxifen alone for the cohorts with and without chemotherapy provide physicians and patients with a comprehensive picture of the risks and benefits when choosing the best adjuvant treatment for these relatively young women.

The Suppression of Ovarian Function Suppression Trial receives financial support for trial conduct from Pfizer, the International Breast Cancer Study Group, and the US National Cancer Institute. Pfizer and Ipsen provide drug supply. Support for the coordinating group International Breast Cancer Study Group is provided by Frontier Science and Technology Research Foundation, Swiss Group for Clinical Cancer Research, US National Cancer Institute Grant No. CA75362 (M.M.R.), Cancer Research Switzerland/Oncosuisse, and the Foundation for Clinical Cancer Research of Eastern Switzerland. Grant support for cooperative groups: Australia and New Zealand Breast Cancer Trials Group: National Health and Medical Research Council Grants No. 351161 and 510788; Southwest Oncology Group: US National Institutes of Health (NIH) Grant No. CA32102; Alliance: US NIH Grant No. U10-CA180821; Eastern Cooperative Oncology Group--American College of Radiology Imaging Network: US NIH Grants No. CA21115 and CA16116; National Surgical Adjuvant Breast and Bowel Project/NRG: US NIH Grants No. U10-CA-12027, U10-CA-69651, U10-CA-37377, and U10-CA-69974; National Cancer Institute of Canada: NIH Grant No. CA077202 and Canadian Cancer Society Research Institute Grants No. 015469 and 021039.

AUTHORS\' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
========================================================

Reply to F. Tomao et al
-----------------------

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO\'s conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [jco.ascopubs.org/site/ifc](http://jco.ascopubs.org/site/ifc).

Karin Ribi
----------

No relationship to disclose

Jürg Bernhard
-------------

No relationship to disclose

Weixiu Luo
----------

No relationship to disclose

Meredith M. Regan
-----------------

**Consulting or Advisory Role:** Merck, Ipsen (Inst)

**Research Funding:** Veridex (Inst), OncoGeneX (Inst), Pfizer (Inst), Ipsen (Inst), Novartis (Inst), Merck (Inst), Ferring Pharmaceuticals (Inst), Celgene (Inst), AstraZeneca (Inst)

Gini F. Fleming
---------------

**Research Funding:** Corcept Therapeutics (Inst)

Prudence A. Francis
-------------------

**Travel, Accommodations, Expenses:** Roche, Pfizer
